Tenderwize
Wróć do wyszukiwania

Non-exclusive discount agreements for Adapalen + Benzoylperoxid

GWQ ServicePlus AG·Düsseldorf, Germany·Deadline Nov 10, 2026 · 26 days left·Open·Supplies
Zarejestruj się, aby zapisaćOpen documents
Structured notice only
Oryginalny tytuł ogłoszenia

Germany – Pharmaceutical products – Abschluss nicht-exklusiver Rabattvereinbarungen nach § 130 a Abs. 8 SGB V mit der Wirkstoffkombination Adapalen + Benzoylperoxid

60/100

Ocena szansy

Needs reviewLow complexity
SuppliesOpen
Skąd ta ocena?

Szansa

60 / 100

Złożoność

30 / 100

Czynniki ryzyka

The non-exclusive nature means there is no commitment from insurers to purchase from you; actual revenue depends on mar...

No estimated contract value is provided, making it difficult to assess potential return on investment.

Głęboka analiza portfolio

Głęboka analiza dopasowania firmy

Wykorzystuje:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Najważniejsze informacje

Zamawiający
GWQ ServicePlus AG
Kraj
Niemcy
CPV
33600000 - Pharmaceutical products
Termin
Nov 10, 2026

Przegląd

Moderate opportunity

Kluczowe fakty

  • Supplies contract
  • 1 lot
  • Duration until Dec 2026
  • Non-exclusive discount agreements (Rabattvereinbarungen) for the active ingredient combination Adapalen + Benzoylperoxid under §130a Abs. 8 SGB V.
  • The agreement allows pharmaceutical companies to offer discounts on the specified pharmaceutical product to participating health insurance funds.
Pokaż pełne podsumowanie

This tender is for non-exclusive discount agreements (Rabattvereinbarungen) for the pharmaceutical combination Adapalen + Benzoylperoxid under §130a Abs. 8 SGB V. The contracting authority, GWQ ServicePlus AG, acts on behalf of German statutory health insurance funds. The procedure is an open admission model (Zulassungsmodell) where any interested pharmaceutical company can join at any time under the same conditions. The initial contract start is 01.04.2025, with a deadline for initial submissions on 10.03.2025. The contract runs until 31.12.2026 with two possible 12-month extensions. No estimated contract value is provided, and no award criteria are specified as this is a non-competitive framework.

Ryzyka

The non-exclusive nature means there is no commitment from insurers to purchase from you; actual revenue depends on mar...

No estimated contract value is provided, making it difficult to assess potential return on investment.

Kluczowe wymagania

Technical

  • Must be a pharmaceutical company with authorization for the product.

Administrative

  • Submit signed contract in duplicate, plus evidence of drug approval (from AMIce database), signed self-declaration (Anlage 3), list of PZNs (Anlage 4), and EU regulation...
  • Submission must be in German via postal mail (electronic submission not allowed).

Wymagania mogą być niepełne.

Zamawiający

Lokalizacja

Düsseldorf, DEU

Profil zamawiającego

Otwórz profil

Identyfikator

DE258895210

Działalność

Health

Części (1)

LOT-0000

Non-exclusive discount agreements for Adapalen + Benzoylperoxid

Non-exclusive discount agreements for the active ingredient combination Adapalen + Benzoylperoxid under §130a Abs. 8 SGB V. The agreement is open to all interested pharmaceutical companies with the relevant product authorization. Contract duration: 01.04.2025 to 31.12.2026, with two possible 12-month extensions.

SuppliesEU fundedElectronic submission

Lokalizacja

DEA11, Germany

Czas trwania

Mar 2025 - Dec 2026

Kategoria

Pharmaceutical products

Termin

Deadline Nov 10, 2026

Szczegóły zamówienia

Data publikacji
18 Feb 2025
Języki
German

Metadane referencyjne

Podstawa prawna
32014L0024

Identyfikatory referencyjne

ID przetargu
112942-2025

Dokumenty (1)

Dokument zamówienia 1

Podobne przetargi

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht-exklusiver Rabattvereinbarungen nach § 130a Abs. 8 SGB V zu den genannten Wirkstoffen mit Abschlussmöglichkeit im Rahmen des sogenannten Open-House-Verfahrens.

Dec 31

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta

Aug 30